PRE Market Analysis

Overview

Fundamentals

P/E ratio
EPS (TTM)$-3.790.0% YoY
Profit margin-63.1%HEALTHCARE
Market cap$287.2MMicro cap

Wall Street coverage

$31.25median target· current $5.78 (+440.7%)2 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
PEG ratio
0.00
P/B
1.65
P/S (TTM)
3.11
EV/EBITDA
0.14

Profitability & growth

ROE (TTM)
-31.8%
Operating margin
-33.3%
Revenue growth YoY
248.6%
Dividend yield
Beta
0.15
Last earnings
Feb 18, 2026 · Estimate $-0.52 · Reported $-0.19
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Prenetics Global Ltd

Prenetics Global Ltd (PRE) is a premier health technology innovator focused on delivering advanced genetic and diagnostic testing solutions that empower consumers and healthcare professionals with critical health insights. With a diverse portfolio of state-of-the-art testing services and integrated digital health offerings, the company has seen significant international growth, fueled by strategic partnerships and a strong commitment to ongoing research and development. As a frontrunner in the personalized medicine space, Prenetics is ideally positioned to capitalize on the increasing demand…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
UNIT 703-706, K11 ATELIER KING?S ROAD, QUARRY BAY
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$287.2M
Shares outstanding$15.3M
52W high$23.63
52W low$5.07

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer